Brainlab Optimizes Planning Processes and Algorithms for Cranial Indications

Brainlab, a global leader in medical technology, will showcase new Elements Cranial SRS* software at this year’s European Society for Radiotherapy & Oncology Meeting—ESTRO 35—April 29-May 3 in Turin, Italy. Elements Cranial SRS offers both research and daily practice opportunities, dovetailing perfectly with ESTRO 35’s focus on multi- and interdisciplinary components in all aspects of radiosurgery treatment.

Strengthened by new intellectual property, exclusively licensed to Brainlab, Elements Cranial SRS features an algorithm that creates patient specific arc trajectories by penalizing geometric collisions with critical structures and rewarding steep dose gradients toward such structures.

“Working closely with our Dalhousie University partners in Halifax, Canada, we have incorporated IP technology into the next generation of Brainlab cranial software that is both innovative and powerful,” said Stefan Vilsmeier, Brainlab President and CEO. “The technology bolsters our already-strong IP in beam pathway optimization. Elements Cranial SRS offers indication-specific, intelligent workflows that automate the procedure so caregivers can spend more time with patients and less time on technology.”

The new intellectual property license will help deliver patient-tailored, optimized arc trajectories aimed at minimizing radiation dose to organs at risk without compromising target coverage. The new algorithm optimizes dose delivery for selected gantry and couch positions. This optimization can be applied to fixed couch arcs as well as simultaneous gantry-couch movements. The software’s planning processes are streamlined and based on clinical need and user necessity.

“Brainlab Elements Cranial SRS is part of a suite of indication-specific and intelligent workflows for stereotactic radiosurgery,” said Claus Promberger, Director Product Portfolio, Brainlab. “Their automation and flexible business model solutions offer value to clinicians and facilities in terms of patient time and investment management.”

*This product is not available for sale and will not be available until all applicable approvals have been obtained.